JC Davies, M Stern, A Dewar, NJ Caplen, FM Munkonge, T Pitt, F Sorgi, L Huang, A Bush, DM Geddes and EW Alton
Department of Paediatric Respiratory Medicine, National Heart and Lung Institute, London, United Kingdom.

Much of the morbidity and mortality seen in cystic fibrosis (CF) is related to chronic infection of the respiratory tract with Pseudomonas aeruginosa. Some studies have attributed the strong relationship between CF and Pseudomonas colonization to the presence of increased numbers of specific cell-surface receptors, although other work suggests that this relates to the presence of mucus. Several groups are now assessing the use of gene transfer as a novel form of treatment for CF. We have examined whether P. aeruginosa binding to freshly obtained CF respiratory epithelial cells is increased, and have studied the effects of transfer of the CF transmembrane conductance regulator (CFTR) gene on this attachment. Binding of P. aeruginosa to noncultured nasal epithelial cells from both CF patients (n = 31) and healthy controls (n = 15) was studied with scanning electron microscopy. Binding was also assessed for CF cells following transfection with CFTR/liposome complexes. Epifluorescence microscopy was used to assess the effects of gene transfer on chloride fluxes. Adherence of P. aeruginosa directly to the cell surface of CF airway epithelium was significantly (P < 0.001) increased over that in non-CF controls. Liposome-mediated CFTR gene transfer resulted in a significant (P < 0.01) reduction in the numbers of bacteria bound to ciliated epithelial cells. Fluorescence microscopy confirmed correction of the basic chloride defect. Thus, in CF, the absence of normal CFTR results in increased binding of P. aeruginosa to respiratory epithelial cells. This abnormality can be corrected in vitro by restoration of CFTR function. This has important implications both for the pathogenesis of CF and for the future application and assessment of gene therapy for this disease.

This article has been cited by other articles:

				E. W. F. W. Alton and on behalf of the United Kingdom Cystic Fibrosis Ge Use of Nonviral Vectors for Cystic Fibrosis Gene Therapy Proceedings of the ATS, December 1, 2004; 1(4): 296 - 301. [Abstract] [Full Text] [PDF]

				D. Oceandy, B. J. McMorran, S. N. Smith, R. Schreiber, K. Kunzelmann, E. W.F.W. Alton, D. A. Hume, and B. J. Wainwright Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities Hum. Mol. Genet., May 1, 2002; 11(9): 1059 - 1067. [Abstract] [Full Text] [PDF]

				P. Scheid, L. Kempster, U. Griesenbach, J.C. Davies, A. Dewar, P.P. Weber, W.H. Colledge, M.J. Evans, D.M. Geddes, and E.W.F.W. Alton Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence Eur. Respir. J., January 1, 2001; 17(1): 27 - 35. [Abstract] [Full Text] [PDF]

				G. A. Gibson, W. G. Hill, and O. A. Weisz Evidence against the acidification hypothesis in cystic fibrosis Am J Physiol Cell Physiol, October 1, 2000; 279(4): C1088 - C1099. [Abstract] [Full Text] [PDF]

				M. M MADLOM; and A. BUSH Guidelines for the ethical conduct of medical research involving children Arch. Dis. Child., October 1, 2000; 83(4): 369d - 369. [Full Text]

				A. BUSH, H. TIDDENS, and M. SILVERMAN Clinical Implications of Inflammation in Young Children Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): S11 - 14. [Full Text] [PDF]

				L. Pizurki, M. A. Morris, M. Chanson, M. Solomon, A. Pavirani, I. Bouchardy, and S. Suter Cystic Fibrosis Transmembrane Conductance Regulator Does Not Affect Neutrophil Migration across Cystic Fibrosis Airway Epithelial Monolayers Am. J. Pathol., April 1, 2000; 156(4): 1407 - 1416. [Abstract] [Full Text] [PDF]

				J. H. Widdicombe Yet Another Role for the Cystic Fibrosis Transmembrane Conductance Regulator Am. J. Respir. Cell Mol. Biol., January 1, 2000; 22(1): 11 - 14. [Full Text]

				D M GEDDES and E W F W ALTON The CF gene: 10 years on Thorax, December 1, 1999; 54(12): 1052 - 1054. [Full Text]

				A Jaffé, A Bush, D M Geddes, and E W F W Alton Prospects for gene therapy in cystic fibrosis Arch. Dis. Child., March 1, 1999; 80(3): 286 - 289. [Full Text]

				S. N. Smith, P. G. Middleton, S. Chadwick, A. Jaffe, K. A. Bush, S. Rolleston, R. Farley, S. J. Delaney, B. Wainwright, D. M. Geddes, et al. The In Vivo Effects of Milrinone on the Airways of Cystic Fibrosis Mice and Human Subjects Am. J. Respir. Cell Mol. Biol., January 1, 1999; 20(1): 129 - 134. [Abstract] [Full Text]

				D. J Davidson and D. J Porteous Genetics and pulmonary medicine bullet  1: The genetics of cystic fibrosis lung disease Thorax, May 1, 1998; 53(5): 389 - 397. [Full Text]